Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma
- Authors
- Sharma, Amit; Kim, Eun-Joong; Mun, Seokgyu; Ji, Myung Sun; Chung, Bong Geun; Kim, Jong Seung
- Issue Date
- 4월-2019
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Cancer; Hepatocellular carcinoma; Theranostic; Targeted therapy; Drug delivery system
- Citation
- DYES AND PIGMENTS, v.163, pp.628 - 633
- Indexed
- SCIE
SCOPUS
- Journal Title
- DYES AND PIGMENTS
- Volume
- 163
- Start Page
- 628
- End Page
- 633
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/66448
- DOI
- 10.1016/j.dyepig.2018.12.026
- ISSN
- 0143-7208
- Abstract
- In past few years, cancer specific targeted drug formulations have shown some hope of improving the therapeutics with minimized associated side effects of chemotherapy. However, the benefits has proven modest due to lack of systems that can be assessed easily from parent drugs while maintaining the same features of cancer associated prodrug activation. We developed a small molecule-based, carboxylesterase responsive theranostic, EDOX, with tumor-specific enzymatic activation for targeted delivery of the anticancer drug, Doxorubicin (Dox), to hepatocellular carcinoma (HCC) cells. Easy synthetic access, physiological stability, tumor-selective activation, and sustained drug release make EDOX an excellent candidate for use as a next-generation drug delivery system for HCC.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Science > Department of Chemistry > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholar.korea.ac.kr/handle/2021.sw.korea/66448)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.